A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 379 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel... June 22, 2021 What’s Your Mantra? July 28, 2021 Foodie Friday: Butternut Squash Macaroni Casserole September 24, 2021 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Load more HOT NEWS Young Woman Considers Service Dog A Crucial Ally In Her Battle... Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... Teenage (…and young adult) kicks
